Advanced Research in Atrial Fibrillation

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1222

Special Issue Editor


E-Mail Website
Guest Editor
Liverpool Heart and Chest Hospital, Liverpool, UK
Interests: atrial fibrillation; electrophysiology; thrombosis

Special Issue Information

Dear Colleagues,

Atrial fibrillation is the most common sustained arrhythmia that is associated with significant morbidity and mortality. Over the past decades, there have been significant advances in the field of atrial fibrillation—both in the understanding of the disease process and various different treatment approaches. Nonetheless, our knowledge on certain aspects of atrial fibrillation such as electrophysiology and arrhythmia mechanisms is lacking. This limits our ability to develop novel therapies in high-risk populations with atrial fibrillation.

In the current Special Issue of Biomedicines entitled ‘Advanced Research in Atrial Fibrillation’, we aim to provide a collection of articles focused on contemporary laboratory and/or experimental research in the field of atrial fibrillation.

We encourage clinicians and scientists to submit original research data, review articles, protocols, etc., relating to atrial fibrillation.

Dr. Wern Yew Ding
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atrial fibrillation
  • arrhythmia
  • electrophysiology
  • cardiovascular
  • mechanism
  • laboratory
  • experimental

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 1326 KiB  
Review
Could the Early Detection of Atrial Fibrillation Reduce the Risk of Developing Dementia?
by Fabrice Demoniere, Rim Abdelli and Léna Rivard
Biomedicines 2024, 12(8), 1931; https://doi.org/10.3390/biomedicines12081931 - 22 Aug 2024
Viewed by 971
Abstract
Atrial fibrillation (AF) and dementia are major global public health issues and share common risk factors, especially after the age of 65 and regardless of the presence of stroke. Despite accounting for potential confounders, AF appears to be an independent risk factor for [...] Read more.
Atrial fibrillation (AF) and dementia are major global public health issues and share common risk factors, especially after the age of 65 and regardless of the presence of stroke. Despite accounting for potential confounders, AF appears to be an independent risk factor for cognitive decline and dementia. The mechanisms are likely to be multifactorial and may include AF-related ischemic stroke, cerebral hypoperfusion, microbleeds, systemic inflammation, genetic factors, and small vessel disease, leading to brain atrophy and white matter damage. The early aggressive management of AF and comorbidities may reduce the risk of dementia. Indeed, the early detection of AF-related cognitive impairment should allow for the early implementation of measures to prevent the development of dementia, mainly through integrative approaches involving the correction of risk factors and maintenance of rhythm control. Well-designed prospective studies are needed to determine whether early detection and AF treatment can prevent dementia and identify whether optimal integrative measures are effective in preventing cognitive impairment and dementia. Full article
(This article belongs to the Special Issue Advanced Research in Atrial Fibrillation)
Show Figures

Figure 1

Back to TopTop